In my opinion, ALT is a buy at $12.00 while awaiting an EUA on either their T-Covid therapy or for their Ad-Covid vaccine. The progress has been slow. It is commonly understood that when working with US Department of Defense, there can be additional layers of approval. The distinguishing feature of the Ad-Covid vaccine is sterilizing immunity, which limits the transmission by individuals vaccinated with Ad-Covid. The claim of sterilizing immunity with Ad-Covid not only protects the individual from disease progression, but Ad-Covid would also stop disease transmission to others. It is regularly mentioned in earnings calls, that other vaccines do not provide sterilizing immunity. Altimmune is also working on NASH, a non-alcoholic version of Hepatitis. Additionally, the firm is developing products to provide protection from Anthrax and Influenza.
June 29th 2021, Altimmune issues statement to discontinue their Ad-Covid trial after seeing disappointing results. Shares fell 39% the following trading day.
